Search results for Hr+/Her2-

Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer

By: Mary Ellen Schneider From: cancertherapyadvisor.com Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-posit...

<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>

Updates In HER2-Low Breast Cancer Treatment Strategies

HER2-low breast cancer has changed one of the most familiar classifications in breast oncology. For many years, tumors that were not HER2-positive were generally managed as HER2-ne...

Low BMI Linked to Progression in HR+/HER2– Breast Cancer Treated With CDK4/6i

By: Vicki Moore, PhD From: cancertherapyadvisor.com A BMI of below 18.5 was associated with progression compared with a reference BMI range of 18.5 to 25 Low body mass index (BMI)...

Oral Paclitaxel DHP107 Non-inferior to IV for Metastatic Breast Cancer

From: oncnursingnews.com Patients with HER2-negative metastatic breast cancer may soon have a more convenient treatment option, as the phase 3 OPTIMAL trial (NCT03315364) confirms...

New Hope for Treating Aggressive Triple Negative Breast Cancer

Cancer is always scary, but few diagnoses carry as much weight as triple negative breast cancer (TNBC). Accounting for 10 to 15 percent of all types of breast cancer cases, this fo...

<![CDATA[FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhi...

EMA Recommends Generic for Advanced/Metastatic Breast Cancer

By: Sophie Cousins From: medscape.com The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting a marketing authorisation for Pa...

New Treatment, Dato-DXd, Improves Survival for Aggressive Breast Cancer

THURSDAY, April 23, 2026 — Triple-negative breast cancer (TNBC) has long been considered one of the most difficult types to fight. It is aggressive, often strikes women under age...

Pumitamig Plus Chemo Drives Strong Responses Across PD-L1 Subgroups of Metastatic TNBC

By: Ashling Wahner From: onclive.com The VEGF/PD-L1–directed bispecific antibody pumitamig (BNT327/BMS986545) has been shown to restore immune activity and improve outcomes in pati...

AstraZeneca, Daiichi Drug Approved as New First-Line Therapy for Tough Type of Breast Cancer

Datroway landed its third FDA approval in the past 18 months, this time as a treatment for triple negative breast cancer. The antibody drug conjugate was developed under a broad co...

A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices

By: Institute of Cancer Research From: medicalxpress.com A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast ca...

New [225Ac]-Pertuzumab Drug Shows Potent HER2 Fight

In the relentless battle against HER2-positive breast cancer, a groundbreaking breakthrough is emerging from the cutting-edge intersection of radiopharmaceuticals and targeted ther...

International Intel: a Glance at the Top Global Breast Cancer News From January-March 2026

By: Ashling Wahner From: onclive.com Key Takeaways China’s NMPA conditionally approved neoadjuvant T-DXd→THP in stage II/III HER2-positive breast cancer, improving pCR to 67.29% ve...

Combination treatment benefits patients with advanced breast cancer that has spread to brain

From: mdanderson.org Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Cent...

Breast cancer’s next precision medicine revolution may lie in molecular residual disease

New data shows potential for ctDNA to guide treatment decisions for patients with triple-negative breast cancer

Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (tras...

Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the...

Spotlight On: Herceptin® (trastuzumab) / Ogivri® (trastuzumab-dkst) / Herzuma® (trastuzumab-pkrb) / Ontruzant® (tras...

Trastuzumab Challenged Claim Types in IPR and Litigation: Claims include those challenged in litigations and IPRs. Claims are counted in each litigation and IPR, so claims from the...

Targetable Markers Define Antiprogestin-Resistant Breast Cancer

In the relentless battle against breast cancer, researchers often confront the formidable challenge of endocrine resistance, particularly prevalent in luminal breast cancers. This...

The New Biomarkers Impacting Cancer Care

When my healthcare provider (HCP) told me I needed HER2 and BRCA testing, I nodded politely like I totally understood everything she was saying. But, in reality, I had no clue what...

This Medication Was Linked To A 56% Lower Risk Of Breast Cancer Recurrence

A widely used medication class may dramatically improve breast cancer survival odds.

This Medication Was Linked To A 56% Lower Risk Of Breast Cancer Recurrence

A widely used medication class may dramatically improve breast cancer survival odds.

Two in Three Early Breast Cancer Patients Fear Recurrence, Yet Low-Risk Assumptions Deter Conversations

At a Glance: One in six HR+/HER2- early breast cancer patients (Stage II & III) face risk of recurrence within 3 years¹ Novartis Malaysia... The post Two in Three Early Breast...

How MRD Testing Is Reshaping Breast Cancer Risk Assessment

New B-59 data shows circulating tumor DNA (ctDNA) and molecular residual disease (MRD) testing can better predict recurrence risk and help guide more personalized care in TNBC.